Crossmark

Progressive loss of glycemic control during chronic DPP-4 inhibitor therapy despite preserved β-cell function: a case report suggesting acquired incretin resistance

Crossref DOI link: https://doi.org/10.1186/s40842-026-00296-2

Published Online: 2026-05-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Prasad, Sai

Ahuja, Aarushi

Sharma, Shreya

Nagda, Jay

Agrawal, Shaily

Parmar, Vidhi

Vardhan, Harsh
License Information

Text and Data Mining valid from 2026-05-20

Version of Record valid from 2026-05-20
More Information

Article History

Received: 24 February 2026

Accepted: 1 April 2026

First Online: 20 May 2026

Declarations

:

: This case report was conducted in accordance with the Declaration of Helsinki. Ethical approval for this case report was waived by the Institutional Ethics Committee. Written informed consent was obtained from the patient for participation in this case report.

: Written informed consent was obtained from the patient for publication of this case report and any accompanying data. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below